Skip to main content
Premium Trial:

Request an Annual Quote

Isis to Receive $1.1M from Alnylam

Premium

Isis Pharmaceuticals this week said that it stands to receive a $1.1 million payment tied to Alnylam Pharmaceuticals' strategic alliance with Genyzme.

This week, Alnylam announced that it has partnered with Genzyme to develop and commercialize RNAi-based treatments for TTR-mediated amyloidosis. Genzyme will have product rights in Asia (see related story, this issue).

Isis said that the money, to be paid by Alnylam, reflects its share of the upfront fees Alnylam is receiving from Genzyme. Isis is entitled to a portion of payments Alnylam receives on licenses to products enabled by Isis intellectual property pursuant to their ongoing IP cross-licensing arrangement.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.